Clinical case shows baricitinib improves morphea symptoms in alopecia areata patients, suggesting JAK/STAT involvement.
In our clinical case, the patient, affected by morphea, reported an excellent response to the administration of baricitinib 4 mg day–1, with rapid disappearance of itching and reduction of the erythematous-infiltrative component of the plaques, highlighting the important role of the JAK/STAT pathway in TGF-β-mediated profibrotic signalling.
No takes yet. Share an insight, caveat, or question.
Rubino et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: